1. With the Efficacy Rate, the Cell Banking Market Evolves…

What ensures a better treatment even than the above figure is banking immune cells when potential patients’ immune cells are healthier, or when patients are at younger stage of the life cycle. The graph below shows that human’s immunity peaks at 20s but would go down trend after that. This gives rise to huge potential of immune cell banking business.



Cancer has been the number one cause of death for human being. Almost one in three would encounter cancer during the course of life. The earlier to reserve the immune cell, the less risk a cancer or a severe disease assaults human body. The immune cell banking opportunity is also the ticket to possible immune-cell therapy opportunity.

2. What We Do

• Immune-cell therapy platform. Vectorite Biomedical (Taiwan 興櫃Ticker: 4170) was founded in Taiwan in 2004. It started as a biotech firm, and is focused on the research and commercialization of active cellular Immune-cell therapy to treat cancers among other diseases. For the past 8 years, the company has worked and conducted more than one hundred clinical trials with renowned life science research institutions and hospitals mainly in the greater China region. In Taiwan, Vectorite is widely known and well respected as the leader in the field of active cellular Immune-cell therapy.
• Immune cell banking platform. Started from 2011, the company has actively been building its immune cell banking business. It provides immune cell banking services which include the collection, processing, testing, cryopreservation and storage of immune cells for our physically healthy customers. The purpose is to preserve and store healthy immune cells when young for potential uses in future Immune-cell therapy treatments.
• The national leader. One of our biggest strengths is the cell-processing technology the company developed as national leader in the field of immune-cell therapy. We have been involved in immune-cell culturing for more than 8 years. Technological know-how, not facilities or equipment, makes the difference in cell processing quality.

3. We Have Built It Into A Creative Duo-Platform Operating Model

Our 2 arms, Cell Banking arm and R&D (or therapy) arm, collaborate with each other, and thus create a unique model for our growth in both cell banking arm and therapy arm. Typically, the cell banking arm would evolve as a unique platform for potential immunotherapy treatment of the growing signup client base.